Cancer-Associated Fibroblasts-Derived Exosomes as Mediators of Immunotherapy Resistance in Head and Neck Squamous Cell Carcinoma
Cells · 2025-12-12 · 14 (24) · 1978
DOI: 10.3390/cells14241978 ↗At a glance
Übersichtsarbeit in Cells, published online on 2025-12-12. Written by Julia Federspiel and 4 co-authors. Institution: Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Innsbruck, A-6020 Innsbruck, Austria. Major MEDLINE topics: Exosomes, Cancer-Associated Fibroblasts, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms. Cited 11 times so far (Crossref); 103 references. The full text is freely available (open access, CC BY 4.0). Funded by: FWF Austrian Science Fund.
Abstract (original language)
The tumor microenvironment (TME) orchestrates tumor growth, immune evasion, and therapeutic response in head and neck squamous cell carcinoma (HNSCC). Current immune checkpoint inhibitors (ICIs) target the programmed death receptor-1/programmed death-ligand 1 (PD-1/PD-L1) axis and improve survival in recurrent, metastatic, and locally advanced HNSCC. Tumor cells produced exosomes directly suppress cytotoxic T-lymphocytes activity by modulating immune checkpoint pathways and disrupting T-cell receptor signaling. Cancer-associated fibroblast-derived exosomes (CAF-Exos) function indirectly by conditioning immune escape and tumor growth. Together, these exosomal populations cooperate to create an immunosuppressive niche that hinders the efficacy of immunotherapies. CAF-Exos induce TME changes that exclude CD8+ T-cells, promote regulatory T-cells (Tregs), and upregulate PD-L1 expression in tumor cells. The bidirectional transfer of microRNAs (miRNAs) between tumor cells and CAFs enhances epithelial–mesenchymal transition (EMT), suppresses cytotoxic lymphocytes, and undermines ICI efficacy. This review article summarizes recent publications about plasma-derived exosomes from HNSCC patients. These exosomes carry tumor and immune checkpoint markers, reflect tumor burden and treatment response, and strongly modulate immune cells by suppressing T- and B-cell activity and promoting immunosuppressive macrophages. We encourage functional and biomechanistic future studies in the field of HNSCC that examine how CAF subtypes exosomes achieve an immunoresistant TME.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Innsbruck, A-6020 Innsbruck, Austria.
- Department of Otorhinolaryngology, TUM Klinikum Rechts der Isar, Technical University of Munich, 81675 München, Germany.
ORCID profiles: Julia Federspiel, Jozsef Dudas, Benedikt Gabriel Hofauer, Barbara Wollenberg, Teresa Bernadette Steinbichler
Funding
- FWF Austrian Science Fund
Cite
APA
Federspiel, J., Dudas, J., Hofauer, B. G., Wollenberg, B., & Steinbichler, T. B. (2025). Cancer-Associated Fibroblasts-Derived Exosomes as Mediators of Immunotherapy Resistance in Head and Neck Squamous Cell Carcinoma. Cells, 14(24), 1978. https://doi.org/10.3390/cells14241978
Vancouver
Federspiel J, Dudas J, Hofauer BG, Wollenberg B, Steinbichler TB. Cancer-Associated Fibroblasts-Derived Exosomes as Mediators of Immunotherapy Resistance in Head and Neck Squamous Cell Carcinoma. Cells. 2025;14(24):1978. doi:10.3390/cells14241978
BibTeX
@article{Federspiel2025,
author = {Federspiel, Julia and Dudas, Jozsef and Hofauer, Benedikt Gabriel and Wollenberg, Barbara and Steinbichler, Teresa Bernadette},
title = {Cancer-Associated Fibroblasts-Derived Exosomes as Mediators of Immunotherapy Resistance in Head and Neck Squamous Cell Carcinoma},
journal = {Cells},
year = {2025},
volume = {14},
number = {24},
pages = {1978},
doi = {10.3390/cells14241978}
}
EUVIMED